Deferasirox

Treats chronic iron overload due to blood transfusions. ANDA 210727, held by Stevens J. Deferasirox.

As of Nov 15, 2026, ANDA 210727 (Deferasirox), held by Stevens J, was first approved by FDA on Jun 15, 2020, with 1 approved supplement and 0 published complete response letters.

First approved: Jun 15, 2020
Review: Standard
Supplements approved: 1
Complete response letters: 0

What It's For

From the FDA-approved label (Indications and Usage)

Deferasirox is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older.

Full prescribing information on DailyMed ↗

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 3 submissions below


Jun 15, 2020	Original application	Approved	None posted
Dec 27, 2019	Original application	Approved	None posted

Products

3 strengths and forms


Deferasirox90MG · tablet;oral	Deferasirox	Discontinued
Deferasirox360MG · tablet;oral	Deferasirox	Discontinued
Deferasirox180MG · tablet;oral	Deferasirox	Discontinued

All 3 submissions, including labeling and manufacturing supplements


Mar 26, 2025	Supplement 2Labeling · Standard review	Approved	None posted
Jun 15, 2020	Original application	Approved	None posted
Dec 27, 2019	Original application	Approved	None posted

Identifiers

Application: ANDA 210727
Drugs@FDA: Overview at FDA
Company: Stevens J

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters